First Patients Treated Using Next Generation CyberKnife System at Oklahoma

                             CyberKnife Center



    SUNNYVALE, Calif., Aug. 5 /EMWNews/ -- Accuray

Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery,

announced today that the first patients were treated using the next

generation CyberKnife(R) Robotic Radiosurgery System that was recently

installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The next generation

CyberKnife System, which features new technologies and system upgrades

announced at the 2007 American Society for Therapeutic Radiology and

Oncology Annual Meeting, is capable of delivering state-of-the-art

radiosurgery with significantly reduced treatment planning and delivery

times.



    Treatment results on the Oklahoma CyberKnife, LLC's first day were

ground-breaking. While treatment times will vary based upon case complexity

and type of cancer, the first patient treated for an intracranial lesion

was completed in only 16 minutes. The next patient, treated for non-small

cell lung cancer, required only 27 minutes of treatment time.



    Incorporating all of the newest enhancements, the next generation

CyberKnife System achieved a considerable reduction in treatment times.

Using the latest advancement in treatment planning, Sequential Optimization

enabled treatment plans to be developed in as little as 15 minutes. With

the new 800 monitor unit/minute linear accelerator treatment times were

reduced with a 30 percent faster rate of dose delivery as compared to

previous systems. Further, the recently launched Iris(TM) Variable Aperture

Collimator enabled very conformal, multi-collimator treatments to be

rapidly delivered to even the most complex targets. And with the new

Optimized Path Traversal feature, treatment times were further reduced with

more efficient robotic motion.



    "This new CyberKnife System configuration now allows us to deliver

radiosurgical quality treatments almost as fast as radiation therapy," said

Greg Spurlock, chief operating officer of US Radiosurgery, the managing

partner of Oklahoma CyberKnife, LLC. "With the CyberKnife System however,

the entire course of therapy is completed in one to five treatments.

Compared to the two month regimen of 30 to 40 treatments required with

conventional radiation therapy, the CyberKnife System clearly benefits both

the patient and the provider."



    Lung cancer treatments with the CyberKnife System are typically

completed in three sessions. The net result of the introduction of these

new technologies is to deliver an entire course of radiosurgery in about

1.5 hours. The shorter treatment regimen of CyberKnife radiosurgery not

only improves patients' quality of life by not requiring a prolonged course

of daily treatment visits, it can also lighten the burden on healthcare

providers, saving time, expense and overhead, while also providing for

significantly greater patient throughput.



    "For all radiation delivery systems, plan quality and treatment time

have historically had an inverse relationship," said Eric P. Lindquist,

senior vice president and chief marketing officer of Accuray Incorporated.

"While other radiosurgery systems actively promote fast treatment times,

plan quality often suffers accordingly. Integrating all of the latest

technologies, CyberKnife treatment times can now be reduced considerably

with absolutely no sacrifice in treatment quality."



    While Oklahoma CyberKnife, LLC purchased its CyberKnife System with all

the next generation upgrades included, those same upgrades were made

available to existing customers through Accuray's Diamond Elite Service

Agreement, which enables customers to choose the right upgrades and payment

plans to fit their technology strategy.



    "We are very pleased with this new ability to efficiently deliver the

highest quality, state-of-the-art radiosurgery to the Tulsa community,"

said Spurlock.

    About the CyberKnife(R) Robotic Radiosurgery System



    The CyberKnife Robotic Radiosurgery System is the world's only robotic

radiosurgery system designed to treat tumors anywhere in the body non-

invasively. Using continual image guidance technology and computer

controlled robotic mobility, the CyberKnife System automatically tracks,

detects and corrects for tumor and patient movement in real-time throughout

the treatment. This enables the CyberKnife System to deliver high-dose

radiation with pinpoint precision, which minimizes damage to surrounding

healthy tissue and eliminates the need for invasive head or body

stabilization frames.



    About Accuray



    Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a

global leader in the field of radiosurgery dedicated to providing an

improved quality of life and a non-surgical treatment option for those

diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic

Radiosurgery System, which extends the benefits of radiosurgery to include

extracranial tumors, including those in the spine, lung, prostate, liver

and pancreas. To date, the CyberKnife System has been used to treat more

than 40,000 patients worldwide and currently more than 130 systems have

been installed in leading hospitals in the Americas, Europe and Asia. For

more information, please visit http://www.accuray.com .



    Safe Harbor Statement



    The foregoing may contain certain forward-looking statements that

involve risks and uncertainties, including uncertainties associated with

the medical device industry. Except for the historical information

contained herein, the matters set forth in this press release, clinical

studies, regulatory review and approval, and market acceptance and

commercialization of products and services are forward-looking statements

within the meaning of the "safe harbor" provisions of the Private

Securities Litigation Reform Act of 1995. Forward-looking statements speak

only as of the date the statements are made and are based on information

available at the time those statements are made and/or management's good

faith belief as of that time with respect to future events. You should not

put undue reliance on any forward-looking statements. Important factors

that could cause actual performance and results to differ materially from

the forward-looking statements we make include: market acceptance of

products; competing products, the combination of our products with

complementary technology; and other risks detailed from time to time under

the heading "Risk Factors" in our report on Form 10-K for the year ended

June 30, 2007 as updated from time to time by our quarterly reports on Form

10-Q and our other filings with the Securities and Exchange Commission. The

Company's actual results of operations may differ significantly from those

contemplated by such forward-looking statements as a result of these and

other factors. We assume no obligation to update forward-looking statements

to reflect actual performance or results, changes in assumptions or changes

in other factors affecting forward-looking information, except to the

extent required by applicable securities laws.